Persistence of subcutaneous infliximab after two years of the switch from intravenous infliximab to subcutaneous infliximab in Inflammatory Bowel Disease patients

被引：0

作者：

Huguet, J. M. ^{[1
]}

Iborra, M. ^{[2
]}

Marti, L. ^{[3
]}

Bosca-Watts, M. M. ^{[4
]}

Ramirez, J. J. ^{[5
]}

Ruiz, L. ^{[1
]}

Sanchis, L. ^{[6
]}

Garrido, A. ^{[2
]}

Alemany, G. ^{[3
]}

Suria, C. ^{[4
]}

Paredes, J. M. ^{[7
]}

机构：

[1] Hosp Gen Univ Valencia, Gastroenterol, Valencia, Spain

[2] Hosp Univ & Politecn Fe Valencia, Gastroenterol, Valencia, Spain

[3] Hosp Francesc Borja Gandia, Gastroenterol, Valencia, Spain

[4] Hosp Clin Univ Valencia, Gastroenterol, Valencia, Spain

[5] Hosp Lluis Alcanyis Xativa, Gastroenterol, Valencia, Spain

[6] Hosp Sagunto, Gastroenterol, Valencia, Spain

[7] Hosp Univ Dr Peset Valencia, Gastroenterol, Valencia, Spain

来源：

JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P657

引用

页码：I1242 / I1242

页数：1

共 50 条

[1] Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients' acceptance
Oliva, B. Caballol
Fernandez-Clotet, A.
Panes, J.
Masamunt, M. C.
Gallego, M.
Barastegui, R.
Vara, A.
Giner, A.
Ricart, E.
Ordas, I.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 618 - 618
[2] The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases
Bothorel, L.
Laharie, D.
Poullenot, F.
Gohier, E.
Chevrier, C.
Berger, A.
Zerbib, F.
Riviere, P.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1490 - I1490
[3] Transition from intravenous to subcutaneous infliximab: effectiveness in a cohort of patients with inflammatory bowel disease
Todeschini, A.
Geccherle, A.
Signoretto, P.
Colaci, N.
Barugola, G.
Variola, A.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1631 - I1631
[4] Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?
Franck, B.
Verdier, M. C.
Bellissant, E.
Bouguen, G.
Lemaitre, F.
Tron, C.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 43 - 43
[5] From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
Verma, Ajay M.
Patel, Anusha
Subramanian, Sreedhar
Smith, Philip J.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 88 - 89
[6] Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at one year
Hancox, S.
Morda, F.
Black, C.
Selinger, C.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1836 - I1836
[7] COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR
Morda, F.
Hancox, S.
Black, C. J.
Selinger, C.
DIGESTIVE AND LIVER DISEASE, 2024, 56 : S239 - S239
[8] Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at 1 year
Hancox, Sarah
Morda, Francesco
Black, Christopher J.
Selinger, Christian Philipp
FRONTLINE GASTROENTEROLOGY, 2025, 16 (01) : 11 - 19
[9] Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy
Gianolio, Laura
Armstrong, Katherine
Swann, Ewan
Shepherd, Rhona
Henderson, Paul
Wilson, David C. C.
Russell, Richard K. K.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (02): : 235 - 239
[10] 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance Therapy
Song, J. H.
Hong, S. N.
Kim, E. R.
Kim, J. E.
Chang, D. K.
Kim, Y. H.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 661 - 662

← 1 2 3 4 5 →